drugset / Trial / NCT07345689

A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations

NCT07345689

Phase 4 Not yet recruiting 60 enrolled Xuanzhu Biopharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the pharmacokinetic profile and safety of anaprazole sodium in adult subjects, particularly including the elderly and those with renal or hepatic impairment.

Timeline

Start
2026-01-30
Primary completion
2026-10-30
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Anaprazole Other / unclassified 20 mg